These biomarkers that are intended to be used in combination with the accepted clinical criteria (i.e., GS, PSA, clinical stage) to stratify PCa according to biological aggressiveness and direct initial patient management have gained considerable popularity; however, additional studies are needed to investigate the clinical benefit of these new technologies, the financial ramifications and how they should be utilized in clinics. This evidence concerns the gene KLK3 and posterior cortical atrophy.